Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

17    Gilead Sciences    $5.5B    up 17.0%
Global revenue: $8.4B (18th); up 6.3%

R&D spend: $1.2B (17th), up 14.5%; 14.6% of rev.

Top brands: Atripla ($2.6B), Truvada ($2.0B); Viread ($466M), Ranexa ($320M), Hepsera ($69M)

Planned launches: Cobicistat (HIV/AIDS), “Quad” pill (HIV/AIDS), GS-7977 (HCV)

Promotional spend: $32M (18th); 0.6% of rev.

Patent expirations: Hepsera (2014), Letairis (2015), Viread (2017)

This specialty biopharma firm remains highly competitive, most notably in antivirals. The leader in the field, Gilead launched HIV/AIDS drug Complera last year and filed the “Quad pill” for approval (set for FDA review in August). Complera and Quad represent important advances, and analysts expect both to get approved and to snag the bulk of new patient starts in coming years, although Gilead's top seller, HIV/AIDS med Atripla, is not scheduled to lose exclusivity until 2021 and despite a generic version of Combivir. The firm also leaped ahead in the hotly contested race to market an all-oral/interferon-free hepatitis C therapy, buying biotech Pharmasset for $11 billion and access to that firm's Phase III pipeline asset GS-7977. The company also plays in the cardiovascular arena, where angina drug Ranexa is selling well, and the FDA's removal of a warning from the label of PAH product Letairis could mean higher sales of that drug. Despite a manufacturing shortage, the drug Cayston also plays an important role in treating pseudomonas aerugonisa in cystic fibrosis patients.

Back to first page

Page 17 of 21
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.